Dublin, Jan. 23, 2017 -- Research and Markets has announced the addition of the "Vascular Dementia Forecast in 13 Major Markets 2017-2027" report to their offering.
Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer disease. It is also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), and is caused by issues with blood supply to the brain, typically caused by a series of minor strokes.
This report provides the current prevalent population for Vascular Dementia across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, United Kingdom, Brazil, Japan, India, China, Republic of Korea and Russian Federation) and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Vascular Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Vascular Dementia include:
- Stroke
- Diabetes
- Heart disease
- Sleep apnoea (linked with hypertension)
- Other dementias
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Vascular Dementia
10. Features of Vascular Dementia patients
11. Significant Comorbid Conditions associated with Vascular Dementia
12. Abbreviations used in the report
13. Patient-Based Offering
14. Online Pricing Data and Platforms
15. References
16. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/6nnp8k/vascular_dementia
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 



